Literature DB >> 19745754

Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts.

Charlotte Lewden1, Rodolphe Thiébaut, Faroudy Boufassa, Ali Coulibaly, Karen Malateste, Rémonie Seng, Thomas D'Aquin Toni, André Inwoley, Christine Rouzioux, Albert Minga, Xavier Anglaret, Laurence Meyer.   

Abstract

OBJECTIVE: We compared CD4+ decline among untreated HIV-1-infected seroconverters living in Côte d'Ivoire (CI) and in France.
METHODS: HIV-1-infected adults were enrolled in the ANRS1220 PRIMO-CI (CI, 1997-2006) and ANRSCO2 SEROCO (France, 1988-1995) cohorts. CD4+ count and percentage declines were estimated from enrollment until 24 months of seroconversion by linear random-effect models adjusted for time since seroconversion, age, gender, cell-associated HIV DNA, HIV RNA, and country.
RESULTS: Overall 521 seroconverters (CI 148, 62% men; France 373, 77% men) were enrolled after a median of 7.6 months since seroconversion. Median follow-up duration was 12.7 months. Median age was 28 years. Median baseline CD4+ count was 472 and 560 cells per cubic millimeter, respectively. Median baseline HIV RNA was 4.4 and 4.0 log10 copies per milliliter and median HIV DNA was 3.0 and 2.8 log10 copies per 10(6) peripheral blood mononuclear cells, respectively. In adjusted models, CD4+ count and percentage at baseline were lower in CI than in France (P < 0.01), and the difference did not vary during follow-up (P = 0.55). Low HIV RNA and low HIV DNA at baseline were associated with higher CD4+ count at baseline.
CONCLUSIONS: CD4+ count and percentage were lower in CI than in France. These differences were already observed during early infection and remained similar after adjustment.

Entities:  

Mesh:

Year:  2010        PMID: 19745754     DOI: 10.1097/QAI.0b013e3181b84260

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

Review 1.  Host genes associated with HIV/AIDS: advances in gene discovery.

Authors:  Ping An; Cheryl A Winkler
Journal:  Trends Genet       Date:  2010-02-10       Impact factor: 11.639

2.  Factors affecting timing of antiretroviral treatment initiation based on monitoring CD4 counts.

Authors:  Farzad Noubary; Michael D Hughes
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

3.  Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters.

Authors:  M Eugenia Socías; Omar Sued; Natalia Laufer; María E Lázaro; Horacio Mingrone; Daniel Pryluka; Carlos Remondegui; María I Figueroa; Carina Cesar; Ana Gun; Gabriela Turk; María B Bouzas; Ravi Kavasery; Alejandro Krolewiecki; Héctor Pérez; Horacio Salomón; Pedro Cahn
Journal:  J Int AIDS Soc       Date:  2011-08-10       Impact factor: 5.396

4.  Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

Authors:  Nikos Pantazis; Charles Morrison; Pauli N Amornkul; Charlotte Lewden; Robert A Salata; Albert Minga; Tsungai Chipato; Harold Jaffe; Shabir Lakhi; Etienne Karita; Kholoud Porter; Laurence Meyer; Giota Touloumi
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

5.  Disease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan: a retrospective observational study.

Authors:  Dai Watanabe; Sachiko Suzuki; Misa Ashida; Yuka Shimoji; Kazuyuki Hirota; Yoshihiko Ogawa; Keishiro Yajima; Daisuke Kasai; Yasuharu Nishida; Tomoko Uehira; Takuma Shirasaka
Journal:  AIDS Res Ther       Date:  2015-05-22       Impact factor: 2.250

6.  Identifying factors associated with changes in CD4(+) count in HIV-infected adults in Saskatoon, Saskatchewan.

Authors:  Kelsey Hunt; Prosanta Mondal; Stephanie Konrad; Stuart Skinner; Kali Gartner; Hyun J Lim
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jul-Aug       Impact factor: 2.471

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.